Priv.-Doz. Dr. Jakob Mühlbacher, PhD
Department of General Surgery (Division of Visceral Surgery)
Position: Consultant
ORCID: 0000-0002-8592-8259
T +43 1 40400 56210
jakob.muehlbacher@meduniwien.ac.at
Keywords
Carcinoma, Pancreatic Ductal; Complement System Proteins; Critical Illness; Intensive Care; Kidney Transplantation
Research group(s)
- VIETAC (Vienna Transplant and Complement Lab)
Members: - Surgical Research Laboratories
Head: Michael Bergmann
Research Area: The task of the laboratory is to combine molecular/cellular biology and the needs posed by surgical patients. Thus, the laboratory acts at the interface between clinical medicine and basic research, promoting translational medical science.
Members: - Pancreatic surgery
Head: Martin Schindl
Research Area: Body composition and inflammation in pancreatic neoplasms.
Members:
Grants
- Torque Teno Virus for the prediction of humoral alloreactivity in liver transplant recipients. (2019)
Source of Funding: Medical Scientific Fund of the Mayor of the City of Vienna, Clinical Research
Principal Investigator
Selected publications
- Tomasich, E. et al. (2024) ‘Immune cell distribution and DNA methylation signatures differ between tumor and stroma enriched compartment in pancreatic ductal adenocarcinoma’, Translational Research, 271, pp. 40–51. Available at: https://doi.org/10.1016/j.trsl.2024.05.005.
- Mühlbacher, J. et al. (2021) ‘Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism’, Transplant International, 34(8), pp. 1542–1552. Available at: https://doi.org/10.1111/tri.13954.
- Mühlbacher, J. et al. 2020. Effect of Intraoperative Goal-Directed Fluid Management on Tissue Oxygen Tension in Obese Patients: a Randomized Controlled Trial, Obesity Surgery, 31(3), pp. 1129–1138. Available at: http://dx.doi.org/10.1007/s11695-020-05106-x.
- Mühlbacher, J. et al., 2020. Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients. Frontiers in Medicine, 7. Available at: http://dx.doi.org/10.3389/fmed.2020.00114.
- Eskandary, F. et al., 2017. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial, American Journal of Transplantation, 18(4), pp. 916–926. Available at: http://dx.doi.org/10.1111/ajt.14528.